SCHEMBL10016658

SCHEMBL10016658

CCCCCCC/C=C/C(=O)NC(CC)CCCCC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.57
TAS1R1 Q7RTX1 1/20 0.57
PSMB11 A5LHX3 1/20 0.46
PSMA7 O14818 1/20 0.46
PSMB1 P20618 1/20 0.46
PSMA1 P25786 1/20 0.46
PSMA2 P25787 1/20 0.46
PSMA3 P25788 1/20 0.46
PSMA4 P25789 1/20 0.46
PSMB8 P28062 1/20 0.46
PSMB9 P28065 1/20 0.46
PSMA5 P28066 1/20 0.46
PSMB4 P28070 1/20 0.46
PSMB6 P28072 1/20 0.46
PSMB5 P28074 1/20 0.46
PSMB10 P40306 1/20 0.46
PSMB3 P49720 1/20 0.46
PSMB2 P49721 1/20 0.46
PSMA6 P60900 1/20 0.46
PSMA8 Q8TAA3 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15205218 1.00 TAS1R3 (0.57) TAS1R3TAS1R1PSMB11PSMA7PSMB1
SCHEMBL15205094 1.00 TAS1R3 (0.57) TAS1R3TAS1R1PSMB11PSMA7PSMB1
SCHEMBL12923993 0.92 TAS1R3 (0.57) TAS1R3TAS1R1PSMB11PSMA7PSMB1
SCHEMBL15205233 0.87 TAS1R3 (0.75) TAS1R3TAS1R1PSMB11PSMA7PSMB1
SCHEMBL10016643 0.87 TAS1R3 (0.75) TAS1R3TAS1R1PSMB11PSMA7PSMB1
SCHEMBL22225439 0.84 TAS1R3 (0.45) TAS1R3TAS1R1CNR1CNR2FFAR1
SCHEMBL8036368 0.80 CNR1 (0.53) TAS1R3TAS1R1PSMB11PSMA7PSMB1
SCHEMBL9467871 0.79 TAS1R3 (0.42) TAS1R3TAS1R1
SCHEMBL6514878 0.79 ZDHHC20 (0.51) FFAR1
SCHEMBL9314536 0.79 ZDHHC20 (0.51) FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2636666-B1 TRANS-2-DECENOIC ACID DERIVATIVE AND MEDICAMENT CONTAINING SAME NAGOYA INDUSTRIAL SCIENCE RES INSTITUTE (JP) 2018-01-10 EP disclosed
CN-103189350-B Trans-2-decenoic acid derivative and drug containing same NAGOYA INDUSTRIAL SCIENCE RESRARCH INSTITUTE (JP) 2016-04-27 CN disclosed
US-20150297562-A1 ANALGESIC NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2015-10-22 US disclosed
US-20150297562-A1 ANALGESIC NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2015-10-22 US disclosed
US-20150297562-A1 ANALGESIC NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2015-10-22 US disclosed
US-8987486-B2 Trans-2-decenoic acid derivative and pharmaceutical agent containing the same NAGOYA INDUSTRIAL SCIENCE RESEARCH INSTITUTE (JP) 2015-03-24 US disclosed
US-8987486-B2 Trans-2-decenoic acid derivative and pharmaceutical agent containing the same NAGOYA INDUSTRIAL SCIENCE RESEARCH INSTITUTE (JP) 2015-03-24 US disclosed
US-8987486-B2 Trans-2-decenoic acid derivative and pharmaceutical agent containing the same NAGOYA INDUSTRIAL SCIENCE RESEARCH INSTITUTE (JP) 2015-03-24 US disclosed
EP-2842553-A1 ANALGESIC Nippon Zoki Pharmaceutical Co., Ltd. (JP) 2015-03-04 EP disclosed
EP-2842553-A1 ANALGESIC Nippon Zoki Pharmaceutical Co., Ltd. (JP) 2015-03-04 EP disclosed
EP-2636666-A1 TRANS-2-DECENOIC ACID DERIVATIVE AND MEDICAMENT CONTAINING SAME Nagoya Industrial Science Research Institute (JP) 2013-09-11 EP disclosed
US-20130225837-A1 TRANS-2-DECENOIC ACID DERIVATIVE AND PHARMACEUTICAL AGENT CONTAINING THE SAME NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2013-08-29 US disclosed
US-20130225837-A1 TRANS-2-DECENOIC ACID DERIVATIVE AND PHARMACEUTICAL AGENT CONTAINING THE SAME NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2013-08-29 US disclosed
US-20130225837-A1 TRANS-2-DECENOIC ACID DERIVATIVE AND PHARMACEUTICAL AGENT CONTAINING THE SAME NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2013-08-29 US disclosed
CN-103189350-A Trans-2-decenoic acid derivative and drug containing same NAGOYA IND SCIENCE RES INST 2013-07-03 CN disclosed
WO-2012060396-A1 TRANS-2-DECENOIC ACID DERIVATIVE AND MEDICAMENT CONTAINING SAME 財団法人名古屋産業科学研究所 (JP) 2012-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150297562-A1 ANALGESIC OPRK1, OPRL1, OPRD1 TAS1R3 2987/4885TAS1R1 3106/4885PSMB11 4056/4885
US-20130225837-A1 TRANS-2-DECENOIC ACID DERIVATIVE AND PHARMACEUTICAL AGENT CONTAINING THE SAME BDNF, NTRK2, NGF TAS1R3 4070/4885TAS1R1 3996/4885PSMB11 4363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.